Revaccination of healthy nonresponders with hepatitis B vaccine and prediction of seroprotection response

Myong Jin Kim; Anne N. Nafziger; Clayton D. Harro; Harry L. Keyserling; Keith M. Ramsey; George L. Drusano; Joseph S. Bertino

doi:10.1016/S0264-410X(02)00626-6

Revaccination of healthy nonresponders with hepatitis B vaccine and prediction of seroprotection response

Myong Jin Kim, Anne N. Nafziger, Clayton D. Harro, Harry L. Keyserling, Keith M. Ramsey, George L. Drusano, Joseph S. Bertino

Bloomberg School of Public Health

Research output: Contribution to journal › Article › peer-review

35 Scopus citations

Abstract

Sixty healthy nonresponders were randomized to receive intramuscular (IM) high dose hepatitis B virus (HBV) vaccine versus IM standard dose HBV vaccine plus granulocyte-macrophage colony-stimulating factor (GM-CSF) at 0-2 months. Antibody to hepatitis B surface antigen was measured 1 month after each dose and 3 months after the last dose. Two regimens were equivalent in eliciting seroprotection in nonresponders. Weight-height index (WHI) <39 and alanine transaminase (ALT) <39mg/dl predicted which nonresponders would seroconvert. A three-dose regimen of standard dose HBV vaccine plus GM-CSF may be a useful for seroprotection of healthy nonresponders.

Original language	English (US)
Pages (from-to)	1174-1179
Number of pages	6
Journal	Vaccine
Volume	21
Issue number	11-12
DOIs	https://doi.org/10.1016/S0264-410X(02)00626-6
State	Published - Mar 7 2003

Keywords

Granulocyte-macrophage colony-stimulating factor
Hepatitis B virus vaccine
Revaccination

ASJC Scopus subject areas

Molecular Medicine
Immunology and Microbiology(all)
veterinary(all)
Public Health, Environmental and Occupational Health
Infectious Diseases

Access to Document

10.1016/S0264-410X(02)00626-6

Cite this

@article{f2fa12867208453e8a55f78a084abf52,

title = "Revaccination of healthy nonresponders with hepatitis B vaccine and prediction of seroprotection response",

abstract = "Sixty healthy nonresponders were randomized to receive intramuscular (IM) high dose hepatitis B virus (HBV) vaccine versus IM standard dose HBV vaccine plus granulocyte-macrophage colony-stimulating factor (GM-CSF) at 0-2 months. Antibody to hepatitis B surface antigen was measured 1 month after each dose and 3 months after the last dose. Two regimens were equivalent in eliciting seroprotection in nonresponders. Weight-height index (WHI) <39 and alanine transaminase (ALT) <39mg/dl predicted which nonresponders would seroconvert. A three-dose regimen of standard dose HBV vaccine plus GM-CSF may be a useful for seroprotection of healthy nonresponders.",

keywords = "Granulocyte-macrophage colony-stimulating factor, Hepatitis B virus vaccine, Revaccination",

author = "Kim, {Myong Jin} and Nafziger, {Anne N.} and Harro, {Clayton D.} and Keyserling, {Harry L.} and Ramsey, {Keith M.} and Drusano, {George L.} and Bertino, {Joseph S.}",

year = "2003",

month = mar,

day = "7",

doi = "10.1016/S0264-410X(02)00626-6",

language = "English (US)",

volume = "21",

pages = "1174--1179",

journal = "Vaccine",

issn = "0264-410X",

publisher = "Elsevier BV",

number = "11-12",

}

TY - JOUR

T1 - Revaccination of healthy nonresponders with hepatitis B vaccine and prediction of seroprotection response

AU - Kim, Myong Jin

AU - Nafziger, Anne N.

AU - Harro, Clayton D.

AU - Keyserling, Harry L.

AU - Ramsey, Keith M.

AU - Drusano, George L.

AU - Bertino, Joseph S.

PY - 2003/3/7

Y1 - 2003/3/7

N2 - Sixty healthy nonresponders were randomized to receive intramuscular (IM) high dose hepatitis B virus (HBV) vaccine versus IM standard dose HBV vaccine plus granulocyte-macrophage colony-stimulating factor (GM-CSF) at 0-2 months. Antibody to hepatitis B surface antigen was measured 1 month after each dose and 3 months after the last dose. Two regimens were equivalent in eliciting seroprotection in nonresponders. Weight-height index (WHI) <39 and alanine transaminase (ALT) <39mg/dl predicted which nonresponders would seroconvert. A three-dose regimen of standard dose HBV vaccine plus GM-CSF may be a useful for seroprotection of healthy nonresponders.

AB - Sixty healthy nonresponders were randomized to receive intramuscular (IM) high dose hepatitis B virus (HBV) vaccine versus IM standard dose HBV vaccine plus granulocyte-macrophage colony-stimulating factor (GM-CSF) at 0-2 months. Antibody to hepatitis B surface antigen was measured 1 month after each dose and 3 months after the last dose. Two regimens were equivalent in eliciting seroprotection in nonresponders. Weight-height index (WHI) <39 and alanine transaminase (ALT) <39mg/dl predicted which nonresponders would seroconvert. A three-dose regimen of standard dose HBV vaccine plus GM-CSF may be a useful for seroprotection of healthy nonresponders.

KW - Granulocyte-macrophage colony-stimulating factor

KW - Hepatitis B virus vaccine

KW - Revaccination

UR - http://www.scopus.com/inward/record.url?scp=0037424116&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0037424116&partnerID=8YFLogxK

U2 - 10.1016/S0264-410X(02)00626-6

DO - 10.1016/S0264-410X(02)00626-6

M3 - Article

C2 - 12559795

AN - SCOPUS:0037424116

VL - 21

SP - 1174

EP - 1179

JO - Vaccine

JF - Vaccine

SN - 0264-410X

IS - 11-12

ER -

Revaccination of healthy nonresponders with hepatitis B vaccine and prediction of seroprotection response

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this